🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 1 día
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 15/02/2008 | 18,35 | 18,50 | 17,79 | 18,39 | -0,49% | 3,87% | 3.104.300 |
| 14/02/2008 | 19,01 | 19,13 | 18,35 | 18,48 | -3,45% | 4,10% | 3.569.400 |
| 13/02/2008 | 18,35 | 19,54 | 18,12 | 19,14 | +11,67% | 7,74% | 10.082.600 |
| 12/02/2008 | 16,38 | 17,29 | 16,04 | 17,14 | -5,88% | 7,63% | 12.942.000 |
| 11/02/2008 | 18,25 | 18,26 | 17,86 | 18,21 | +0,61% | 2,19% | 2.200.400 |
| 08/02/2008 | 18,96 | 19,25 | 17,59 | 18,10 | -4,79% | 8,76% | 3.577.800 |
| 07/02/2008 | 19,25 | 19,38 | 18,48 | 19,01 | -1,91% | 4,68% | 2.258.600 |
| 06/02/2008 | 19,86 | 19,86 | 19,02 | 19,38 | -1,32% | 4,23% | 2.485.500 |
| 05/02/2008 | 20,07 | 20,09 | 19,47 | 19,64 | -3,25% | 3,09% | 1.780.500 |
| 04/02/2008 | 20,49 | 20,59 | 20,08 | 20,30 | -1,31% | 2,49% | 1.888.500 |
| 01/02/2008 | 20,51 | 20,86 | 19,86 | 20,57 | +1,03% | 4,88% | 1.631.000 |
| 31/01/2008 | 20,14 | 20,44 | 19,92 | 20,36 | +1,50% | 2,58% | 1.570.300 |
| 30/01/2008 | 20,51 | 20,66 | 20,06 | 20,06 | -2,86% | 2,93% | 1.639.900 |
| 29/01/2008 | 20,50 | 21,30 | 20,47 | 20,65 | +1,92% | 4,05% | 2.116.800 |
| 28/01/2008 | 19,22 | 20,60 | 19,12 | 20,26 | +5,69% | 7,70% | 2.442.800 |
| 25/01/2008 | 19,39 | 19,39 | 18,81 | 19,17 | -0,47% | 2,99% | 3.596.600 |
| 24/01/2008 | 19,75 | 19,85 | 18,80 | 19,26 | -3,80% | 5,32% | 4.580.400 |
| 23/01/2008 | 20,20 | 21,45 | 19,13 | 20,02 | -10,51% | 11,49% | 8.026.500 |
| 22/01/2008 | 22,26 | 23,01 | 22,11 | 22,37 | -2,01% | 4,04% | 1.769.700 |
| 18/01/2008 | 23,38 | 23,52 | 22,42 | 22,83 | -2,93% | 4,70% | 2.820.800 |
| 17/01/2008 | 23,89 | 24,27 | 23,14 | 23,52 | -0,76% | 4,73% | 2.668.700 |
| 16/01/2008 | 24,08 | 24,67 | 23,34 | 23,70 | +4,27% | 5,52% | 3.553.100 |
| 15/01/2008 | 21,16 | 23,05 | 21,15 | 22,73 | +1,43% | 8,98% | 2.423.900 |
| 14/01/2008 | 22,89 | 22,91 | 22,29 | 22,41 | -0,84% | 2,71% | 1.592.900 |
| 11/01/2008 | 22,08 | 22,89 | 22,00 | 22,60 | +1,07% | 4,03% | 1.447.900 |
| 10/01/2008 | 21,56 | 22,64 | 21,56 | 22,36 | +2,99% | 5,01% | 1.925.200 |
| 09/01/2008 | 21,60 | 21,96 | 21,29 | 21,71 | -0,69% | 3,10% | 2.279.800 |
| 08/01/2008 | 20,96 | 22,18 | 20,85 | 21,86 | +4,39% | 6,35% | 2.756.700 |
| 07/01/2008 | 21,26 | 21,57 | 20,74 | 20,94 | -2,60% | 3,90% | 2.337.200 |
| 04/01/2008 | 21,30 | 22,20 | 20,92 | 21,50 | +0,28% | 6,01% | 3.378.600 |